Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African-American and Caucasian Volunteers

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

(2010) Awewura Kwara et al.   AIDS

Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

(2010) E. T. Ogburn et al.   DRUG METABOLISM AND DISPOSITION

Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

(2010) Heather J. Ribaudo et al.   JOURNAL OF INFECTIOUS DISEASES

Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism

(2010) L. Oleson et al.   XENOBIOTICA

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults

(2010) Sumonmal Uttayamakul et al.   AIDS Research and Therapy

Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin

(2009) Matthijs van Luin et al.   AIDS

Successful genotype-tailored treatment with small-dose efavirenz

(2009) Hiroyuki Gatanaga et al.   AIDS

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

(2009) Awewura Kwara et al.   AIDS

CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India

(2009) G. Ramachandran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Body Weight Cutoff for Daily Dosage of Efavirenz and 60-Week Efficacy of Efavirenz-Based Regimen in Human Immunodeficiency Virus and Tuberculosis Coinfected Patients Receiving Rifampin

(2009) W. Manosuthi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CYP2B6(c.516G→T) andCYP2A6(*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

(2009) Awewura Kwara et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine

(2009) A.-S. Belanger et al.   DRUG METABOLISM AND DISPOSITION

Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis

(2009) Yuan Ren et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients:UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation

(2009) Awewura Kwara et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efavirenz–rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

(2008) Salvador E Cabrera et al.   AIDS

Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect ofCYP2B6Variation

(2008) Awewura Kwara et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Are Literature References Sufficient for Dose Recommendations? An FDA Case Study of Efavirenz and Rifampin

(2008) Jennifer L. DiGiacinto et al.   JOURNAL OF CLINICAL PHARMACOLOGY